New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
09:25 EDTAVTH, AVTH, SSET, SSET, AWK, AWK, NBS, NBS, SNWV, SNWV, ATNM, ATNM, VTEQ, VTEQ, AKER, AKER, CGIX, CGIX, DIRI, DIRIRedChip Companies to hold a virtual conference
Global Online CEO Conference to be held on July 16-17 with webcasted presentations to begin on July 16 at 9:30 am. Webcast Link
News For AVTH;CGIX;AKER;VTEQ;ATNM;SNWV;NBS;AWK;SSET;DIRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTAWKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:16 EDTNBSPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
06:39 EDTAWKAmerican Water upgraded to Outperform from Neutral at RW Baird
Subscribe for More Information
March 24, 2015
07:10 EDTATNMActinium Pharmaceuticals opens enrollment for fourth cohort in Phase I/II Trial
Actinium Pharmaceuticals announced that the company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia, or AML, in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the company's investigational new drug Actimab-A at a higher activity level of 2.0 ýCi/kg per dose. In the previously completed third cohort in which patients received two doses of Actimab-A at 1.5 ýCi/kg per dose two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery, or CRi. These responses were documented in the settings of high pre-treatment leukemia burdens of up to 80% in the bone marrow. In the second cohort treated at a lower dose level of Actimab-A of 1.0 ýCi/kg per dose, one patient achieved CRi.
March 23, 2015
16:40 EDTAWKAmerican Water coverage resumed with a Buy at Janney Capital
Target $62.
March 20, 2015
07:42 EDTATNM, NBSBioCentury to hold a conference
Subscribe for More Information
March 18, 2015
09:23 EDTATNMOn The Fly: Pre-market Movers
Subscribe for More Information
07:08 EDTATNMActinium Pharmaceuticals announces new data from Actimab-A Phase 1/2 trial
Actinium Pharmaceuticals announced the completion of the third cohort of the company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia, or AML, in elderly patients. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery. These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use